Published in Prog Neuropsychopharmacol Biol Psychiatry on June 01, 2013
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) | NCT00021528
Mice with altered BDNF signaling as models for mood disorders and antidepressant effects. Front Behav Neurosci (2014) 0.99
TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. Mol Psychiatry (2016) 0.86
Additive gene-environment effects on hippocampal structure in healthy humans. J Neurosci (2014) 0.86
Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network. Clin Pharmacol Ther (2016) 0.86
Epigenetic mechanisms underlying the role of brain-derived neurotrophic factor in depression and response to antidepressants. J Exp Biol (2015) 0.83
From psychiatric disorders to animal models: a bidirectional and dimensional approach. Biol Psychiatry (2014) 0.83
Clinical and genetic factors associated with suicide in mood disorder patients. Eur Arch Psychiatry Clin Neurosci (2015) 0.83
Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report. Clin Psychopharmacol Neurosci (2015) 0.83
Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms. Br J Clin Pharmacol (2014) 0.82
A Longitudinal Study of BDNF Promoter Methylation and Depression in Breast Cancer. Psychiatry Investig (2015) 0.80
Schizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models. Front Psychiatry (2015) 0.79
Antidepressant treatment response is modulated by genetic and environmental factors and their interactions. Ann Gen Psychiatry (2014) 0.78
HIV-1 proteins accelerate HPA axis habituation in female rats. Physiol Behav (2015) 0.78
Horizons of psychiatric genetics and epigenetics: where are we and where are we heading? Iran J Psychiatry Behav Sci (2014) 0.78
The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder. PLoS One (2014) 0.78
5-HT2A Gene Variants Moderate the Association between PTSD and Reduced Default Mode Network Connectivity. Front Neurosci (2016) 0.77
Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway. BMC Psychiatry (2016) 0.75
Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis. J Headache Pain (2017) 0.75
The establishment of the objective diagnostic markers and personalized medical intervention in patients with major depressive disorder: rationale and protocol. BMC Psychiatry (2016) 0.75
Disproportionate Reduction of Serotonin Transporter May Predict the Response and Adherence to Antidepressants in Patients with Major Depressive Disorder: A Positron Emission Tomography Study with 4-[18F]-ADAM. Int J Neuropsychopharmacol (2015) 0.75
Pharmacogenomic Testing for Psychotropic Medication Selection: A Systematic Review of the Assurex GeneSight Psychotropic Test. Ont Health Technol Assess Ser (2017) 0.75
HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis. Int J Neuropsychopharmacol (2016) 0.75
Associations between Serotonergic Genes and Escitalopram Treatment Responses in Patients with Depressive Disorder and Acute Coronary Syndrome: The EsDEPACS Study. Psychiatry Investig (2015) 0.75
Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry (2017) 0.75
Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry. EPMA J (2017) 0.75
Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. Eur Arch Psychiatry Clin Neurosci (2017) 0.75
Mindfulness based cognitive therapy for psychiatric disorders: a systematic review and meta-analysis. Psychiatry Res (2010) 3.46
Mindfulness-based stress reduction for stress management in healthy people: a review and meta-analysis. J Altern Complement Med (2009) 2.89
Does mindfulness training improve cognitive abilities? A systematic review of neuropsychological findings. Clin Psychol Rev (2010) 2.17
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97
The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. Eur Arch Psychiatry Clin Neurosci (2012) 1.70
Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry (2007) 1.60
Mindfulness-based interventions for chronic pain: a systematic review of the evidence. J Altern Complement Med (2011) 1.54
Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. Am J Med Genet B Neuropsychiatr Genet (2003) 1.50
The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder. Eur Arch Psychiatry Clin Neurosci (2012) 1.49
Antidepressant effects of light therapy combined with sleep deprivation are influenced by a functional polymorphism within the promoter of the serotonin transporter gene. Biol Psychiatry (2003) 1.48
HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia. J Clin Psychopharmacol (2015) 1.42
Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial. J Clin Psychopharmacol (2005) 1.41
Seasonal variations of lithium plasma levels. Psychiatry Res (2002) 1.38
Are mindfulness-based interventions effective for substance use disorders? A systematic review of the evidence. Subst Use Misuse (2013) 1.37
Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression. Am J Med Genet B Neuropsychiatr Genet (2007) 1.35
Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol (2011) 1.33
Pharmacogenetics of antidepressant response. J Psychiatry Neurosci (2011) 1.28
Personality and attempted suicide. Analysis of anger, aggression and impulsivity. J Psychiatr Res (2009) 1.26
Mindfulness: top-down or bottom-up emotion regulation strategy? Clin Psychol Rev (2012) 1.14
ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.14
A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett (2004) 1.11
Interaction between serotonin transporter gene, catechol-O-methyltransferase gene and stressful life events in mood disorders. Int J Neuropsychopharmacol (2006) 1.10
Gene environment interaction studies in depression and suicidal behavior: An update. Neurosci Biobehav Rev (2013) 1.07
Possible association between -G308A tumour necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population. Psychiatr Genet (2003) 1.07
The 5-HTTLPR polymorphism and eating disorders: a meta-analysis. Int J Eat Disord (2011) 1.05
Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett (2004) 1.04
Depressive symptomatology is influenced by chronotypes. J Affect Disord (2009) 1.02
A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett (2004) 1.02
Serotonergic genes and suicide: a systematic review. Eur Neuropsychopharmacol (2013) 1.01
Cognitive status, depressive symptoms, and health status as predictors of functional disability among elderly persons with low-to-moderate education: The Faenza Community Aging Study. Am J Geriatr Psychiatry (2005) 0.99
Focus on HTR2C: A possible suggestion for genetic studies of complex disorders. Am J Med Genet B Neuropsychiatr Genet (2009) 0.99
Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol (2011) 0.98
Retrospective analysis of psychomotor agitation, hypomanic symptoms, and suicidal ideation in unipolar depression. Depress Anxiety (2006) 0.98
BanI polymorphism of the cytosolic phospholipase A2 gene and mood disorders in the Korean population. Neuropsychobiology (2004) 0.98
Mindfulness-based cognitive therapy versus psycho-education for patients with major depression who did not achieve remission following antidepressant treatment: a preliminary analysis. J Altern Complement Med (2012) 0.98
The 5-HTTLPR polymorphism and posttraumatic stress disorder: a meta-analysis. J Trauma Stress (2013) 0.98
Psychological mechanisms of mindfulness-based interventions: what do we know? Holist Nurs Pract (2014) 0.98
Genetics of late-onset Alzheimer's disease: update from the alzgene database and analysis of shared pathways. Int J Alzheimers Dis (2011) 0.97
Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. Clin Neuropharmacol (2011) 0.97
Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am J Med Genet B Neuropsychiatr Genet (2009) 0.96
Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol (2011) 0.96
Influence of BDNF variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Neuropsychobiology (2011) 0.93
How do genes exert their role? Period 3 gene variants and possible influences on mood disorder phenotypes. Eur Neuropsychopharmacol (2007) 0.93
Serum concentrations of CRP, IL-6, TNF-α and cortisol in major depressive disorder with melancholic or atypical features. Psychiatry Res (2012) 0.93
Catechol-o-methyltransferase gene modulation on suicidal behavior and personality traits: review, meta-analysis and association study. J Psychiatr Res (2010) 0.93
Serotonin transporter 5HTTLPR polymorphism and affective disorders: no evidence of association in a large European multicenter study. Eur J Hum Genet (2004) 0.93
From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment. Can J Psychiatry (2014) 0.93
Polymorphisms of heat shock protein 70 gene (HSPA1A, HSPA1B and HSPA1L) and schizophrenia. Neurosci Res (2005) 0.92
Occurrence of cognitive impairment and dementia after the age of 60: a population-based study from Northern Italy. Dement Geriatr Cogn Disord (2004) 0.92
Newer antidepressants and panic disorder: a meta-analysis. Int Clin Psychopharmacol (2013) 0.92
Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up. J Affect Disord (2008) 0.91
Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. Eur Arch Psychiatry Clin Neurosci (2011) 0.91
Pharmacogenetics of antidepressant response: an update. Hum Genomics (2009) 0.89
Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs (2008) 0.89
The role of COMT gene variants in depression: Bridging neuropsychological, behavioral and clinical phenotypes. Neurosci Biobehav Rev (2013) 0.89
Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet (2013) 0.89
Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: an exploratory analysis. Psychiatry Clin Neurosci (2006) 0.88
Psychometric characteristic of the Italian version of the Temperament and Character Inventory--revised, personality, psychopathology, and attachment styles. Compr Psychiatry (2008) 0.88
Paroxetine for the treatment of depression: a critical update. Expert Opin Pharmacother (2012) 0.88
Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects. Eur Neuropsychopharmacol (2009) 0.87
Quetiapine XR: current status for the treatment of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.87
Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. Prog Neuropsychopharmacol Biol Psychiatry (2008) 0.87
Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. Eur Arch Psychiatry Clin Neurosci (2011) 0.87
Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. Biomed Pharmacother (2008) 0.86
5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Int J Neuropsychopharmacol (2007) 0.86
Correlation of a set of gene variants, life events and personality features on adult ADHD severity. J Psychiatr Res (2009) 0.86
Clinical, psychological and environmental predictors of prospective suicide events in patients with Bipolar Disorder. J Psychiatr Res (2013) 0.86
Potential role of membrane-bound COMT gene polymorphisms in female depression vulnerability. J Affect Disord (2013) 0.86
Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. Eur Neuropsychopharmacol (2009) 0.86
Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population. Psychiatr Genet (2004) 0.86
European Group for the Study of Resistant Depression (GSRD)--where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol (2012) 0.86
Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. Prog Neuropsychopharmacol Biol Psychiatry (2011) 0.86
Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. J Psychiatr Res (2009) 0.85
Effect of 5-haplotype of dysbindin gene (DTNBP1) polymorphisms for the susceptibility to bipolar I disorder. Am J Med Genet B Neuropsychiatr Genet (2007) 0.85
Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. World J Biol Psychiatry (2011) 0.85
Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants. Psychiatr Genet (2006) 0.85
Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment. Pharmacogenet Genomics (2014) 0.84
Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications. Curr Psychiatry Rep (2015) 0.84
Interaction between SERTPR and stressful life events on response to antidepressant treatment. Eur Neuropsychopharmacol (2008) 0.84
Monocyte chemoattractant protein-1 (MCP1) promoter -2518 polymorphism may confer a susceptibility to major depressive disorder in the Korean population. Psychiatry Res (2004) 0.83
Interleukin-10 gene promoter polymorphism is not associated with schizophrenia in the Korean population. Psychiatry Clin Neurosci (2003) 0.83
MAOA and MAOB polymorphisms and anger-related traits in suicidal participants and controls. Eur Arch Psychiatry Clin Neurosci (2012) 0.83
AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment. Eur Neuropsychopharmacol (2012) 0.83
Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. Int J Neuropsychopharmacol (2004) 0.83
Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre. BMC Psychiatry (2006) 0.83
Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int J Neuropsychopharmacol (2002) 0.83
5-HT 1A polymorphism and self-transcendence in mood disorders. Am J Med Genet B Neuropsychiatr Genet (2005) 0.83
Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. Expert Opin Pharmacother (2009) 0.83
Association analysis of heat shock protein 70 gene polymorphisms in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2008) 0.83
Serious suicidal behaviors: socio-demographic and clinical features in a multinational, multicenter sample. Nord J Psychiatry (2013) 0.83
Temperament and character of suicide attempters. J Psychiatr Res (2007) 0.83
Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord (2005) 0.83
Association study between glutathione S-transferase P1 polymorphism and schizophrenia in the Korean population. Prog Neuropsychopharmacol Biol Psychiatry (2003) 0.83
HTR1B as a risk profile maker in psychiatric disorders: a review through motivation and memory. Eur J Clin Pharmacol (2009) 0.83
The impact of heat shock protein 70 gene variations on clinical presentation and outcome in schizophrenic inpatients. Neuropsychobiology (2009) 0.83
The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes. Prog Neurobiol (2011) 0.83